Gene-expression differences in peripheral blood between lithium responders and non-responders in the Lithium Treatment-Moderate dose Use Study (LiTMUS)

Pharmacogenomics Journal

Volumn 14, Issue 2, 2014, Pages 182-191

  Beech, R D ^a   Leffert, J J ^a   Lin, A ^a   Sylvia, L G ^b   Umlauf, S ^a   Mane, S ^a   Zhao, H ^a   Bowden, C ^c   Calabrese, J R ^d   Friedman, E S ^e   Ketter, T A ^f   Iosifescu, D V ^g   Reilly Harrington, N A ^b   Ostacher, M ^f   Thase, M E ^h   Nierenberg, A ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MOUNT SINAI MEDICAL CENTER   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

BCL2L1; Bipolar disorder; Gene expression; Lithium response; Microarray

Indexed keywords

LITHIUM; BCL2L1 PROTEIN, HUMAN; PLASMA PROTEIN; PROTEIN BCL X;

ADULT; ARTICLE; BCL2L1 GENE; BIPOLAR DISORDER; BLOOD EXAMINATION; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; GENE; GENE CONTROL; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE; BIOSYNTHESIS; CLINICAL TRIAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY;

BCL-X PROTEIN; BIPOLAR DISORDER; BLOOD PROTEINS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LITHIUM; MALE;

EID: 84897398654     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2013.16     Document Type: Article

References (65)

1. Cade JF. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 2: 349-352.
2. APA. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 2002; 159(4 Suppl): 1-50.
3. Grof P, Muller-Oerlinghausen B. A critical appraisal of lithium's efficacy and effectiveness: the last 60 years. Bipolar Disord 2009; 11: 10-19.
4. Tondo L, Hennen J, Baldessarini RJ. Lower suicide risk with long-term lithium treatment in major affective illness: a meta-analysis. Acta Psychiatr Scand 2001; 104: 163-172.
5. Ernst CL, Goldberg JF. Antisuicide properties of psychotropic drugs: a critical review. Harv Rev Psychiatry 2004; 12: 14-41.
6. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Revicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 2003; 290: 1467-1473.
7. Kleindienst N, Engel R, Greil W. Which clinical factors predict response to prophylactic lithium? A systematic review for bipolar disorders. Bipolar Disord 2005; 7: 404-417.
8. Serretti A, Lilli R, Lorenzi C, Gasperini M, Smeraldi E. Tryptophan hydroxylase gene and response to lithium prophylaxis in mood disorders. J Psychiatr Res 1999; 33: 371-377.
9. Turecki G, Grof P, Cavazzoni P, Duffy A, Grof E, Ahrens B et al. Evidence for a role of phospholipase C-gamma1 in the pathogenesis of bipolar disorder. Mol Psychiatry 1998; 3: 534-538.
10. Steen VM, Lovlie R, Osher Y, Belmaker RH, Berle JO, Gulbrandsen AK. The polymorphic inositol polyphosphate 1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness. Pharmacogenetics 1998; 8: 259-268.
11. Rybakowski JK, Suwalska A, Skibinska M, Szczepankiewicz A, Leszczynska-Rodziewicz A, Permoda A et al. Prophylactic lithium response and polymorphism of the brain-derived neurotrophic factor gene. Pharmacopsychiatry 2005; 38: 166-170.
12. Serretti A, Lilli R, Mandelli L, Lorenzi C, Smeraldi E. Serotonin transporter gene associated with lithium prophylaxis in mood disorders. Pharmacogenomics J 2001; 1: 71-77.
13. Cavazzoni P, Alda M, Turecki G, Rouleau G, Grof E, Martin R et al. Lithiumresponsive affective disorders: no association with the tyrosine hydroxylase gene. Psychiatry Res 1996; 64: 91-96.
14. Lovlie R, Berle JO, Stordal E, Steen VM. The phospholipase C-gamma1 gene (PLCG1) and lithium-responsive bipolar disorder: re-examination of an intronic dinucleotide repeat polymorphism. Psychiatr Genet 2001; 11: 41-43.
15. Michelon L, Meira-Lima I, Cordeiro Q, Miguita K, Breen G, Collier D et al. Association study of the INPP1, 5HTT, BDNF, AP-2beta and GSK-3beta GENE variants and restrospectively scored response to lithium prophylaxis in bipolar disorder. Neurosci Lett 2006; 403: 288-293.
16. Masui T, Hashimoto R, Kusumi I, Suzuki K, Tanaka T, Nakagawa S et al. Lithium response and Val66Met polymorphism of the brain-derived neurotrophic factor gene in Japanese patients with bipolar disorder. Psychiatr Genet 2006; 16: 49-50.
17. Perlis RH, Smoller JW, Ferreira MA, McQuillin A, Bass N, Lawrence J et al. A genomewide association study of response to lithium for prevention of recurrence in bipolar disorder. Am J Psychiatry 2009; 166: 718-725.
18. Belmaker RH, Agam G. Bipolar disorder: neurochemistry and drug mechanisms. Discov Med 2005; 5: 191-198.
19. Seelan RS, Khalyfa A, Lakshmanan J, Casanova MF, Parthasarathy RN. Deciphering the lithium transcriptome: Microarray profiling of lithium-modulated gene expression in human neuronal cells. Neuroscience 2007; 151: 1184-1197.
20. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 2000; 48: 740-754.
21. Einat H, Manji HK. Cellular plasticity cascades: genes-to-behavior pathways in animal models of bipolar disorder. Biol Psychiatry 2006; 59: 1160-1171.
22. Gladkevich A, Kauffman HF, Korf J. Lymphocytes as a neural probe: potential for studying psychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28: 559-576.
23. Sullivan PF, Fan C, Perou CM. Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 2006; 141: 261-268.
24. Lowthert L, Leffert J, Lin A, Umlauf S, Maloney K, Muralidharan A et al. Increased ratio of anti-apoptotic to pro-apoptotic Bcl2 gene-family members in lithiumresponders onemonth after treatment initiation. Biol Mood Anxiety Disord 2012; 2: 15.
25. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56-62.
26. Nierenberg AA, Friedman ES, Bowden CL, Sylvia LG, Thase ME, Ketter T et al. Lithium Treatment Moderate-Dose Use Study (LiTMUS) for bipolar disorder: a randomized comparative effectiveness trial of optimized personalized treatment with and without lithium. Am J Psychiatry 2013; 170: 102-110.
27. Nierenberg AA, Sylvia LG, Leon AC, Reilly-Harrington NA, Ketter TA, Calabrese JR et al. Lithium treatment-moderate dose use study (LiTMUS) for bipolar disorder: rationale and design. Clin Trials 2009; 6: 637-648.
28. Suppes T, Dennehy EB, Hirschfeld RM, Altshuler LL, Bowden CL, Calabrese JR et al. The Texas implementation of medication algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry 2005; 66: 870-886.
29. Spearing MK, Post RM, Leverich GS, Brandt D, Nolen W. Modification of the Clinical Global Impressions (CGI) Scale for use in bipolar illness (BP): the CGI-BP. Psychiatry Res 1997; 73: 159-171.
30. Illumina. Normalization and Differential Analysis. BeadStudio Gene Expression Module v3. 2 User Guide vol. 2009. Illumina Technical SupportSan Diego, CA, 2009.
31. Reiner A, Yekutieli D, Benjamini Y. Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics 2003; 19: 368-375.
32. Storey JD, Xiao W, Leek JT, Tompkins RG, Davis RW. Significance analysis of time course microarray experiments. Proc Natl Acad Sci USA 2005; 102: 12837-12842.
33. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2009; 4: 44-57.
34. Broer A, Brookes N, Ganapathy V, Dimmer KS, Wagner CA, Lang F et al. The astroglial ASCT2 amino acid transporter as a mediator of glutamine efflux. J Neurochem 1999; 73: 2184-2194.
35. Gegelashvili M, Rodriguez-Kern A, Pirozhkova I, Zhang J, Sung L, Gegelashvili G. High-affinity glutamate transporter GLAST/EAAT1 regulates cell surface expression of glutamine/neutral amino acid transporter ASCT2 in human fetal astrocytes. Neurochem Int 2006; 48: 611-615.
36. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7: 41-53.
37. Verrey F, System L. heteromeric exchangers of large, neutral amino acids involved in directional transport. Pflugers Arch 2003; 445: 529-533.
38. Nicklin P, Bergman P, Zhang B, Triantafellow E, Wang H, Nyfeler B et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell 2009; 136: 521-534.
39. Cleary C, Linde JA, Hiscock KM, Hadas I, Belmaker RH, Agam G et al. Antidepressive-like effects of rapamycin in animal models: implications for mTOR inhibition as a new target for treatment of affective disorders. Brain Res Bull 2008; 76: 469-473.
40. Betz H, Gomeza J, Armsen W, Scholze P, Eulenburg V. Glycine transporters: essential regulators of synaptic transmission. Biochem Soc Trans 2006; 34(Pt 1): 55-58.
41. Deng X, Sagata N, Takeuchi N, Tanaka M, Ninomiya H, Iwata N et al. Association study of polymorphisms in the neutral amino acid transporter genes SLC1A4, SLC1A5 and the glycine transporter genes SLC6A5, SLC6A9 with schizophrenia. BMC Psychiatry 2008; 8: 58.
42. Perez-Siles G, Morreale A, Leo-Macias A, Pita G, Ortiz AR, Aragon C et al. Molecular basis of the differential interaction with lithium of glycine transporters GLYT1 and GLYT2. J Neurochem 2011; 118: 195-204.
43. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell 2004; 116: 205-219.
44. Adams JM, Cory S. Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol 2007; 19: 488-496.
45. Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem 1999; 72: 879-882.
46. Manji HK, Moore GJ, Chen G. Lithium up-regulates the cytoprotective protein Bcl-2 in the CNS in vivo: a role for neurotrophic and neuroprotective effects in manic depressive illness. J Clin Psychiatry 2000; 61(Suppl 9): 82-96.
47. Bachmann RF, Wang Y, Yuan P, Zhou R, Li X, Alesci S et al. Common effects of lithium and valproate on mitochondrial functions: protection against methamphetamine-induced mitochondrial damage. Int J Neuropsychopharmacol 2009; 12: 1-18.
48. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-1657.
49. Vasudevan KM, Garraway LA. AKT signaling in physiology and disease. Curr Top Microbiol Immunol 2010; 347: 105-133.
50. Detera-Wadleigh SD. Lithium-related genetics of bipolar disorder. Annf Med 2001; 33: 272-285.
51. Chuang DM. The antiapoptotic actions of mood stabilizers: molecular mechanisms and therapeutic potentials. Ann NY Acad Sci 2005; 1053: 195-204.
52. Mora AL, Corn RA, Stanic AK, Goenka S, Aronica M, Stanley S et al. Antiapoptotic function of NF-kappaB in T lymphocytes is influenced by their differentiation status: roles of Fas, c-FLIP, and Bcl-xL. Cell Death Differ 2003; 10: 1032-1044.
53. Qian J, Zou Y, Rahman JS, Lu B, Massion PP. Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. Mol Cancer Ther 2009; 8: 101-109.
54. Wada T, Penninger JM. Mitogen-activated protein kinases in apoptosis regulation. Oncogene 2004; 23: 2838-2849.
55. Fan S, Meng Q, Laterra JJ, Rosen EM. Role of Src signal transduction pathways in scatter factor-mediated cellular protection. J Biol Chem 2009; 284: 7561-7577.
56. Chu F, Borthakur A, Sun X, Barkinge J, Gudi R, Hawkins S et al. The Siva-1 putative amphipathic helical region (SAH) is sufficient to bind to BCL-XL and sensitize cells to UV radiation induced apoptosis. Apoptosis 2004; 9: 83-95.
57. Xue L, Chu F, Cheng Y, Sun X, Borthakur A, Ramarao M et al. Siva-1 binds to and inhibits BCL-X(L)-mediated protection against UV radiation-induced apoptosis. Proc Natl Acad Sci USA 2002; 99: 6925-6930.
58. Gudi R, Barkinge J, Hawkins S, Prabhakar B, Kanteti P. Siva-1 promotes K-48 polyubiquitination of TRAF2 and inhibits TCR-mediated activation of NF-kappaB. J Environ Pathol, Toxicol Oncol 2009; 28: 25-38.
59. Fuchs BC, Finger RE, Onan MC, Bode BP. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells. Am J Physiol Cell Physiol 2007; 293: C55-C63.
60. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012; 62: 35-41.
61. Jin Y, Sui HJ, Dong Y, Ding Q, Qu WH, Yu SX et al. Atorvastatin enhances neurite outgrowth in cortical neurons in vitro via up-regulating the Akt/mTOR and Akt/GSK-3beta signaling pathways. Acta Pharmacol Sin 2012; 33: 861-872.
62. Fulda S. Modulation of mitochondrial apoptosis by PI3K inhibitors. Mitochondrion 2012; 13: 195-198.
63. Beech RD, Lowthert L, Leffert JJ, Mason PN, Taylor MM, Umlauf S et al. Increased peripheral blood expression of electron transport chain genes in bipolar depression. Bipolar Disord 2010; 12: 813-824.
64. Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 2005; 170: 1101-1111.
65. Wang Z, Wang J, Li J, Wang X, Yao Y, Zhang X et al. MEK/ERKs signaling is essential for lithium-induced neurite outgrowth in N2a cells. Int J Dev Neurosci 2011; 29: 415-422.